Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Allo-HCT Impact on Lymphoplasmacytic Lymphoma
Biol Blood Marrow Transplant; ePub 2016 Oct 24; Cornell, et al
Allo-HCT led to robust survival in some people with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, according to a study involving 134 individuals.
Investigators looked at long-term outcomes in participants who were a median 53 years of age and had a median time from diagnosis to transplant of 41 months. Patients received either myeloablative (n=67) or reduced intensity conditioning (n=67). Among the results:
- Progression free survival, overall survival, rate of relapse, and non-relapse mortality at 5-years were 46%, 52%, 24%, and 30%, respectively.
- Patients with chemo-sensitive disease and better pre-transplant disease status had better overall survival.
- Conditioning or graft source had no significant impact on progression-free survival.
- Conditioning intensity did not impact treatment-related mortality or relapse.
Cornell R, Bachanova V, D'Souza A, et al. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. [Published online ahead of print October 24, 2016]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2016.10.010.